ArticleCurrent topics in medicinal chemistry2026
An Exosome-Liposome Hybrid Platform for Celastrol Delivery Enhances Anti-Tumor Efficacy in Hepatocellular Carcinoma.
Article in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionCelastrol (CEL), a promising agent for HCC treatment, is greatly restricted in clinical use because of its extremely low water solubility and high systemic toxicity. Novel delivery to enhance its therapeutic index is a key challenge.
methodsThis study constructed a novel biomimetic hybrid nanodelivery system (CEL-Lipo-Exo) by the fusion of CEL-encapsulated liposome (CEL-Lipo) with exosomes derived from immortalized human mesenchymal stem cells. The in vitro and in vivo physicochemistry, anti-tumor efficacy, and toxicomechanistic properties of the nanoparticles were systematically characterized.
resultsThe resulting CEL-Lipo-Exo nanoparticle system showed uniform size distribution (100 nm), preserved essential features of exosomes, and high loading capacity (EE75%). In vitro, CELLipo- Exo more efficiently suppressed HCC cell growth and reduced cell migration and invasion, as well as caused greater apoptosis than free CEL and control liposomes. In vivo, the CEL-Lipo-Exo demonstrated the strongest inhibitory activities against tumors and completely abolished free CELinduced systemic toxicity. DISCUSSION: The efficacy of converting a potent but cytotoxic natural compound to an effective nontoxic drug can be enhanced using the exosome-liposome hybrid concept. Utilizing the exosome shell as a biological camouflage, this platform surmounts the major barriers of celastrol for clinical application, thereby suggesting that biomimetic nanomedicine could be a solution for challenging drug candidates.
conclusionThis CEL-Lipo-Exo nanoplatform is a very promising approach for the seeking of "safe and efficient" carriers of celastrol, suggesting an emerging target strategy for HCC therapy.
Indexed as
Identifiers
41820787What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.